Key points from article :
ChromaDex has announced results of the 18th clinical trial on its flagship Niagen (patented nicotinamide riboside) supplement ingredient.
Adds to a growing body of clinical evidence supporting the potential anti-inflammatory effects of NR supplements.
Monocytes (a type of white blood cell that is produced in the bone marrow) had been extracted from two groups: young, healthy subjects and patients diagnosed with systemic lupus erythematosus.
SLE is an autoimmune disease in which the immune system attacks the body’s own tissues.
Results showed that increasing NAD+ levels through NR supplements reduced Type-I interferon (IFN) signalling.
“This study supplies a mechanistic foundation as to how NR blunts monocyte immunity and supports the need for future studies in patients with monocyte-driven inflammatory disease ...” - Michael Sack, study lead.
Randomised, double-blinded, placebo-controlled pilot study featured 35 healthy volunteers (average age of 24).
Participants were supplemented with 1000mg NR or placebo for 7 days.
Research published in Journal of Clinical Investigation.
